Thomas L. Ingram

Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX.